tradingkey.logo

BRIEF-Sanofi/Regeneron: Dupixent® (dupilumab) sBLA accepted for FDA Priority Review for the targeted treatment of Bullous Pemphigoid (BP)

ReutersFeb 18, 2025 6:02 AM

- Regeneron Pharmaceuticals Inc REGN.O/SANOFI SASY.PA

  • DUPIXENT® (DUPILUMAB) SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TARGETED TREATMENT OF BULLOUS PEMPHIGOID (BP)

  • DUPIXENT® (DUPILUMAB) SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TARGETED TREATMENT OF BULLOUS PEMPHIGOID (BP)

  • DUPIXENT® (DUPILUMAB) SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR TARGETED TREATMENT OF BULLOUS PEMPHIGOID (BP)

  • FDA DECISION ON THIS ON DUPIXENT EXPECTED BY JUNE 20, 2025

Source text: ID:nGNXf53dj

Further company coverage: REGN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI